86 results on '"Byrne, K."'
Search Results
2. P578 Evolution of Crohnʼs disease treatment in clinical practice: a 25 year single centre cohort study
3. P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease
4. P261 Grading post-operative recurrence in Crohnʼs disease: a comparison between MRE and ileocolonoscopy
5. Posterodorsal Medial Amygdala Mediates Tail-Pinch Induced Food Intake in Female Rats
6. LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations: 140PD
7. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): 138PD
8. XRCC6BP1: A key DNA repair gene in platinum-resistant NSCLC: 80P
9. Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC: 75P
10. Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells: 67P
11. Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?: 70P
12. Elucidating drug resistance mechanisms using 2D and 3D culture systems: 74P
13. Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer: 68P
14. The overexpression of SASH1 stimulates cell death in lung cancer cells: 16P
15. Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma: 17P
16. CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer: 24P
17. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
18. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
19. Relative Importance of the Arcuate and Anteroventral Periventricular Kisspeptin Neurons in Control of Puberty and Reproductive Function in Female Rats
20. Overexpression of Corticotropin Releasing Factor in the Central Nucleus of the Amygdala Advances Puberty and Disrupts Reproductive Cycles in Female Rats
21. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
22. Neurokinin B Receptor Antagonism Decreases Luteinising Hormone Pulse Frequency and Amplitude and Delays Puberty Onset in the Female Rat
23. Risk of skin cancer in patients with inflammatory bowel disease: BI12
24. Genomic architecture of histone 3 lysine 27 trimethylation during late ovine skeletal muscle development
25. Force of removal for untunnelled, tunnelled and double-tunnelled peripheral nerve catheters*
26. Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials: ID 242
27. The utility of 18F-FDG PET imaging in staging, response assessment, and re-staging of Merkel cell carcinoma: 082 – Scientific Paper
28. Suppression of the GnRH Pulse Generator by Neurokinin B Involves a κ-Opioid Receptor-Dependent Mechanism
29. Analysis of the Recovery of Cryopreserved and Thawed CD34 and CD3 Cells: S67-030K
30. Bone matters in lung cancer
31. The extent and nature of need for mealtime support among adults with intellectual disabilities
32. The Role of GABAergic Signalling in Stress-Induced Suppression of Gonadotrophin-Releasing Hormone Pulse Generator Frequency in Female Rats
33. Fifty years of Sudanese hospital-based obstetric outcomes and an international partnership
34. S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC
35. S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes
36. S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients
37. S88 Day case cisplatin delivery for advanced NSCLC patients: faster, cheaper, more desirable
38. A Comparison of Small Volume Red Blood Cell Preservation Methods: SP338
39. Experience with Donor Reentry Testing for Hepatitis B Core Antibody: SP125
40. Mapping the information resources available to patients with colorectal cancer
41. Corticotrophin-Releasing Factor Alters the Timing of Puberty in the Female Rat
42. Neonatal Lipopolysaccharide Exposure Delays Puberty and Alters Hypothalamic Kiss1 and Kiss1r mRNA Expression in the Female Rat
43. Targeting histone deacetylases for the treatment of disease
44. Down-Regulation of Hypothalamic Kisspeptin and its Receptor, Kiss1r, mRNA Expression is Associated with Stress-Induced Suppression of Luteinising Hormone Secretion in the Female Rat
45. Neonatal Lipopolysaccharide Exposure Exacerbates Stress-Induced Suppression of Luteinizing Hormone Pulse Frequency in Adulthood
46. The Molecular Basis of a KEL1 Variant Red Cell Phenotype: SP347
47. Analysis of gene expression during the onset of muscle hypertrophy in callipyge lambs
48. Identification of a KEL7 subtype: implications for genotyping red blood cell Jsa and Jsb antigens
49. Differential Role of Corticotrophin-Releasing Factor Receptor Types 1 and 2 in Stress-Induced Suppression of Pulsatile Luteinising Hormone Secretion in the Female Rat
50. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.